IllnessIntellectual deficit, cerebro-organic; differential diagnosis
Summary
Comprehensive differential diagnostic panel for Intellectual deficit, cerebro-organic, comprising 11 or altogether 101 curated genes according to the clinical signs
277,6 kb (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
NGS +
[Sanger]
Gene panel
Selected genes
Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
---|---|---|---|---|
CASK | 2766 | NM_003688.3 | XL | |
DCX | 1083 | NM_178153.3 | XL | |
EIF2B5 | 2166 | NM_003907.3 | AD | |
FOXP2 | 2148 | NM_014491.4 | AD | |
SNX14 | 2841 | NM_153816.6 | AR | |
TSC1 | 3495 | NM_000368.5 | AD | |
TUBA1A | 1356 | NM_006009.4 | AD | |
TUBB | 1335 | NM_178014.4 | AD | |
TUBB2A | 1338 | NM_001069.3 | AD | |
TUBB2B | 1338 | NM_178012.5 | AD | |
TUBB3 | 1353 | NM_006086.4 | AD | |
TUBG1 | 1356 | NM_001070.5 | AD | |
ABCD1 | 2238 | NM_000033.4 | XLR | |
ACO2 | 2343 | NM_001098.3 | AR, AD | |
ADGRG1 | 2064 | NM_005682.7 | AR | |
AIMP1 | 939 | NM_004757.4 | AR | |
AMPD2 | 2478 | NM_001368809.2 | AR | |
APC2 | 6912 | NM_005883.3 | AR | |
ARFGEF2 | 5358 | NM_006420.3 | AR | |
BLTP1 | 15018 | NM_015312.4 | AR | |
CA8 | 873 | NM_004056.6 | AR | |
CAMTA1 | 5022 | NM_015215.4 | AD | |
CCND2 | 870 | NM_001759.4 | AD | |
CDON | 3795 | NM_016952.5 | AD | |
CHMP1A | 591 | NM_002768.5 | AR | |
CLN3 | 1317 | NM_001042432.2 | AR | |
CLN5 | 1077 | NM_006493.4 | AR | |
CLN6 | 936 | NM_017882.3 | AR | |
CLN8 | 861 | NM_018941.4 | AR | |
CLP1 | 1086 | NM_001142597.2 | AR | |
CNOT1 | 7401 | NM_001265612.2 | AD | |
CNTNAP2 | 3996 | NM_014141.6 | AR | |
CRADD | 600 | NM_003805.5 | AR | |
CRB2 | 3858 | NM_173689.7 | AR | |
CTNNA2 | 2583 | NM_001164883.2 | AR | |
CTSD | 1239 | NM_001909.5 | AR | |
DARS1 | 1506 | NM_001349.4 | AR | |
DARS2 | 1938 | NM_018122.5 | AR | |
DEGS1 | 1018 | NM_003676.4 | AR | |
EMC1 | 2979 | NM_001271427.2 | AR | |
EML1 | 2448 | NM_004434.3 | AR | |
EMX2 | 759 | NM_004098.4 | AD | |
EXOSC3 | 828 | NM_016042.4 | AR | |
FAT4 | 14946 | NM_024582.6 | AR | |
FLNA | 7920 | NM_001456.4 | XL | |
GJC2 | 1320 | NM_020435.4 | AR | |
GLI2 | 4761 | NM_005270.5 | AD | |
HEPACAM | 1251 | NM_152722.5 | AD, AR | |
HYCC1 | 1566 | NM_032581.4 | AR | |
KCTD7 | 870 | NM_153033.5 | AR | |
KIF2A | 2235 | NM_001098511.3 | AD | |
KIF5C | 2874 | NM_004522.3 | AD | |
KIF7 | 4032 | NM_198525.3 | AR | |
LAMB1 | 5361 | NM_002291.3 | AR | |
LAMC3 | 4728 | NM_006059.4 | AR | |
MACF1 | 16293 | NM_012090.5 | AD | |
MLC1 | 1134 | NM_015166.4 | AR | |
MTOR | 7650 | NM_004958.4 | AD | |
NDE1 | 1008 | NM_001143979.2 | AR | |
NF1 | 8457 | NM_001042492.3 | AD | |
OCLN | 1569 | NM_002538.4 | AR | |
OPHN1 | 2409 | NM_002547.3 | XLR | |
PAFAH1B1 | 1233 | NM_000430.4 | AD | |
PLA2G6 | 2421 | NM_003560.4 | AR | |
PLP1 | 834 | NM_000533.5 | XLR | |
POLR3A | 4173 | NM_007055.4 | AR | |
POLR3B | 3402 | NM_018082.6 | AR, AD | |
PPT1 | 921 | NM_000310.4 | AR | |
PSAP | 1575 | NM_002778.4 | AR | |
PYCR2 | 741 | NM_013328.4 | AR | |
RAC3 | 589 | NM_005052.3 | AD | |
RALA | 625 | NM_005402.4 | AD | |
RARS1 | 1983 | AR | ||
RARS2 | 1737 | NM_020320.5 | AR | |
RELN | 10383 | NM_005045.4 | AR | |
RNASET2 | 771 | NM_003730.6 | AR | |
RXYLT1 | 1355 | NM_014254.3 | AR | |
SEPSECS | 1506 | NM_016955.4 | AR | |
SHH | 1389 | NM_000193.4 | AD | |
SIX3 | 999 | NM_005413.4 | AD | |
SLC12A6 | 3453 | NM_133647.2 | AR | |
TBC1D23 | 2100 | NM_001199198.3 | AR | |
TBCD | 7465 | NM_005993.5 | AR | |
TGIF1 | 819 | NM_173208.3 | AD | |
TMTC3 | 2745 | NM_181783.4 | AR | |
TMX2 | 899 | NM_015959.4 | AR | |
TOE1 | 1488 | NM_025077.4 | AR | |
TPP1 | 1692 | NM_000391.4 | AR | |
TSC2 | 5424 | NM_000548.5 | AD | |
TSEN2 | 1398 | NM_025265.4 | AR | |
TSEN34 | 933 | NM_024075.5 | AR | |
TSEN54 | 1581 | NM_207346.3 | AR | |
TUBB4A | 1335 | NM_006087.4 | AD | |
UBTF | 2295 | NM_014233.4 | AD | |
UFM1 | 405 | NM_001286704.2 | AR | |
VLDLR | 2622 | NM_003383.5 | AR | |
VPS53 | 2499 | NM_001128159.3 | AR | |
VRK1 | 1191 | NM_003384.3 | AR | |
WDR45 | 1086 | NM_007075.4 | XL | |
ZIC2 | 1599 | NM_007129.5 | AD |
Informations about the disease
Mental retardation (currently accepted English term, intellectual deficits) is a lifelong debilitating condition affecting up to 2-3% of the population in Western countries. While the causal pathogenesis is extremely variable, genetic etiologies are the most common cause, detectable in >50% of patients. This percentage is increasing in the face of efficient NGS technologies. Brain malformations cause quite a few cases of intellectual deficits and comprise a group of genetic developmental brain disorders that present in childhood with intellectual disability (and other neurological features). In some cases, malformations of the forebrain, midbrain/hindbrain and cortex result from de novo or somatic mutation events at the gamete or postzygotic stage, but many cases of brain malformations are the result of rare, heritable causes. In particular, gene mutations for holoprosencephaly, agenesis of the corpus callosum, septo-optic dysplasia, pontocerebellar and cerebellar hypoplasia, Dandy-Walker malformation, molar tooth sign, microcephaly, megalencephaly, lissencephaly, heterotopia, polymicrogyria, schizencephaly and focal cortical dysplasias are comprised here. Autosomal dominant and recessive as well as X-linked inheritance patterns are observed. DNA diagnostic yield is increasing but is currently impossible to quantify accurately overall. Clinical diagnosis can in no way be ruled out by a negative molecular genetic result.
References: Medizinische Genetik 3/2018
- Alias: Intellectual disability, brain organic
- Alias: Psycho-motor retardation, btrain organic
- Allelic: Autism susceptibility 15 (CNTNAP2)
- Allelic: Epilepsy, familial temporal lobe, 7 (RELN)
- Allelic: Fibrosis of extraocular muscles, congenital, 3A (TUBB3)
- Allelic: Focal segmental glomerulosclerosis 9 (CRB2)
- Allelic: Hennekam lymphangiectasia-lymphedema syndrome 2 (FAT4)
- Allelic: Hydranencephaly with abnormal genitalia (ARX)
- Allelic: Leukemia, juvenile myelomonocytic (NF1)
- Allelic: Lymphangioleiomyomatosis (TSC1)
- Allelic: Lymphatic malformation 3 (GJC2)
- Allelic: Microhydranencephaly (NDE1)
- Allelic: Microphthalmia with coloboma 5 (SHH)
- Allelic: Neurofibromatosis, familial spinal (NF1)
- Allelic: Optic atrophy 9 (ACO2)
- Allelic: Parkinson disease 14, AR (PLA2G6)
- Allelic: Parkinson disease 24, AD, susceptibility to (PSAP)
- Allelic: Pitt-Hopkins like syndrome 1 (CNTNAP2)
- Allelic: Single median maxillary central incisor (SHH)
- Allelic: Sotos syndrome 3 (APC2)
- Allelic: Spastic paraplegia 44, AR (GJC2)
- Allelic: Spastic paraplegia 63 (AMPD2)
- Allelic: Subcortical laminar heterotopia (PAFAH1B1)
- Allelic: Symmetric circumferential skin creases, congenital, 1 (TUBB)
- Allelic: Vissers-Bodmer syndrome (CNOT1)
- Allelic: Watson syndrome (NF1)
- Adrenoleukodystrophy (ABCD1)
- Adrenomyeloneuropathy, adult (ABCD1)
- Agenesis of the corpus callosum with peripheral neuropathy (SLC12A6)
- Alkuraya-Kucinskas syndrome (KIAA1109))
- Band heterotopia (EML1)
- Cerebellar ataxia + mental retardation with/-out quadrupedal locomotion 3 (CA8)
- Cerebellar ataxia, nonprogressive, with mental retardation (CAMTA1)
- Cerebellar atrophy, visual impairment + psychomotor retardation (EMC1)
- Cerebellar hypoplasia + mental retardation with/-out quadrupedal locomotion 1 (VLDLR)
- Ceroid lipofuscinosis, neuronal, 1 (PPT1)
- Ceroid lipofuscinosis, neuronal, 10 (CTSD)
- Ceroid lipofuscinosis, neuronal, 2 (TPP1)
- Ceroid lipofuscinosis, neuronal, 3 (CLN3)
- Ceroid lipofuscinosis, neuronal, 4A [Kufs type], AR (CLN6)
- Ceroid lipofuscinosis, neuronal, 5 (CLN5)
- Ceroid lipofuscinosis, neuronal, 6 (CLN6)
- Ceroid lipofuscinosis, neuronal, 8 (CLN8)
- Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant (CLN8)
- Combined SAP deficiency (PSAP)
- Cortical dysplasia, complex, with other brain malformations 1 (TUBB3)
- Cortical dysplasia, complex, with other brain malformations 10 (APC2)
- Cortical dysplasia, complex, with other brain malformations 2 (KIF5C)
- Cortical dysplasia, complex, with other brain malformations 3 (KIF2A)
- Cortical dysplasia, complex, with other brain malformations 4 (TUBG1)
- Cortical dysplasia, complex, with other brain malformations 5 (TUBB2A)
- Cortical dysplasia, complex, with other brain malformations 6 (TUBB)
- Cortical dysplasia, complex, with other brain malformations 7 (TUBB2B)
- Cortical dysplasia, complex, with other brain malformations 8 (TUBA8)
- Cortical dysplasia-focal epilepsy syndrome (CNTNAP2)
- Cortical malformations, occipital (LAMC3)
- Culler-Jones syndrome (GLI2)
- Developmental + epileptic encephalopathy 1 (ARX)
- Dystonia 4, torsion, AD (TUBB4A)
- Encephalopathy, progressive, early-onset, with brain atrophy + thin corpus callosum (TBCD)
- Epilepsy, progressive myoclonic 3, with/-out intracellular inclusions (KCTD7)
- FG syndrome 4 (CASK)
- Focal cortical dysplasia, type II, somatic (MTOR)
- Focal cortical dysplasia, type II, somatic (TSC1)
- Gaucher disease, atypical (PSAP)
- Hiatt-Neu-Cooper neurodevelopmental syndrome (RALA)
- Holoprosencephaly 11 (CDON)
- Holoprosencephaly 12, with/-out pancreatic agenesis (CNOT1)
- Holoprosencephaly 2 (SIX3)
- Holoprosencephaly 3 (SHH)
- Holoprosencephaly 4 (TGIF1)
- Holoprosencephaly 5 (ZIC2)
- Holoprosencephaly 9 (GLI2)
- Hypomyelination with brainstem + spinal cord involvement + leg spasticity (DARS1)
- Infantile cerebellar-retinal degeneration (ACO2)
- Infantile neuroaxonal dystrophy 1 (PLA2G6)
- Krabbe disease, atypical (PSAP)
- Leukodystrophy, hypomyelinating, 10 (PYCR2)
- Leukodystrophy, hypomyelinating, 14 (UFM1)
- Leukodystrophy, hypomyelinating, 18 (DEGS1)
- Leukodystrophy, hypomyelinating, 2 (GJC2)
- Leukodystrophy, hypomyelinating, 3 (AIMP)
- Leukodystrophy, hypomyelinating, 5 (FAM126A)
- Leukodystrophy, hypomyelinating, 6 (TUBB4A)
- Leukodystrophy, hypomyelinating, 7, with/-out oligodontia +/- hypogonadotr. hypogonadism (POLR3A)
- Leukodystrophy, hypomyelinating, 8, with/-out oligodontia +/- hypogonadotr. hypogonadism (POLR3B)
- Leukoencephalopathy with brain stem + spinal cord involvement + lactate elevation (DARS2)
- Leukoencephalopathy with vanishing white matter (EIF2B5)
- Leukoencephalopathy, cystic, without megalencephaly (RNASET2)
- Lissencephaly 1 (PAFAH1B1)
- Lissencephaly 2 [Norman-Roberts type] (RELN)
- Lissencephaly 3 (TUBA1A)
- Lissencephaly 4 [with microcephaly] (NDE1) Lissencephaly 8 (TMTC3)
- Lissencephaly 5 (LAMB1)
- Lissencephaly 9 with complex brainstem malformation (MACF1)
- Lissencephaly, XL (DCX)
- Lissencephaly, XL 2 (ARX)
- Megalencephalic leukoencephalopathy with subcortical cysts (MLC1)
- Megalencephalic leukoencephalopathy with subcortical cysts 2A (HEPACAM)
- Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitt., +/- ment. retard. (HEPACAM)
- Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 (CCND2)
- Mental retardation, AR 34, with variant lissencephaly (CRADD)
- Mental retardation, XL 29 + others (ARX)
- Mental retardation, XL, with cerebellar hypoplasia + distinctive facial appearance (OPHN1)
- Mental retardation, microcephaly with pontine + cerebellar hypoplasia (CASK)
- Mental retardation, with or without nystagmus (CASK)
- Metachromatic leukodystrophy due to SAP-b deficiency (PSAP)
- Muscular dystrophy-dystroglycanopathy (cong. with brain + eye anomalies), type A, 10 (RXYLT1)
- Neurodegeneration with brain iron accumulation 2B (PLA2G6)
- Neurodegeneration with brain iron accumulation 5 (WDR45)
- Neurodegeneration, childhood-onset, with brain atrophy (UBTF)
- Neurodevelopmental disorder with microcephaly, cortical malformations + spasticity (TMX2)
- Neurodevelopmental disorder with structural brain anomalies + dysmorphic facies (RAC3)
- Neurofibromatosis, type 1 (NF1)
- Neurofibromatosis-Noonan syndrome (NF1)
- Ovarioleukodystrophy (EIF2B5)
- Partington syndrome (ARX)
- Pelizaeus-Merzbacher disease (PLP1)
- Periventricular heterotopia with microcephaly (ARFGEF2)
- Polymicrogyria, bilateral frontoparietal (ADGRG1)
- Polymicrogyria, bilateral perisylvian (ADGRG1)
- Pontocerebellar hypoplasia type 10 (CLP1)
- Pontocerebellar hypoplasia type 11 (TBC1D23)
- Pontocerebellar hypoplasia type 1A (VRK1)
- Pontocerebellar hypoplasia type 1B (EXOC3)
- Pontocerebellar hypoplasia type 2A (TSEN54)
- Pontocerebellar hypoplasia type 2B (TSEN2)
- Pontocerebellar hypoplasia type 2C (TSEN34)
- Pontocerebellar hypoplasia type 2D (SEPSECS)
- Pontocerebellar hypoplasia type 2E (VPS53)
- Pontocerebellar hypoplasia type 4 (TSEN54)
- Pontocerebellar hypoplasia type 5 (TSEN54)
- Pontocerebellar hypoplasia type 6 (RARS2)
- Pontocerebellar hypoplasia type 8 (CHMP1A)
- Pontocerebellar hypoplasia type 9 (AMPD2)
- Pontocerebellar hypoplasia, type 7 (TOE1)
- Proud syndrome (ARX)
- Pseudo-TORCH syndrome 1 (OCLN)
- Schizencephaly (EMX2)
- Schizencephaly (SHH)
- Schizencephaly (SIX3)
- Smith-Kingsmore syndrome (MTOR)
- Spastic paraplegia 2, XL (PLP1)
- Speech-language disorder-1 (FOXP2)
- Spinocerebellar ataxia, AR 20 (SNX14)
- Spinocerebellar ataxia, AR 7 (TPP1)
- Subcortical laminal heterotopia, XL (DCX)
- Tuberous sclerosis-1 (TSC1)
- Van Maldergem syndrome 2 (FAT4)
- Ventriculomegaly with cystic kidney disease (CRB2)
- Wiedemann-Rautenstrauch syndrome (POLR3A)
- AD
- AR
- XL
- XLR
- Multiple OMIM-Ps
Bioinformatics and clinical interpretation
Test-Stärken
- DAkkS-akkreditiertes Labor
- EU-Richtlinie für IVD in Umsetzung
- Qualitäts-kontrolliert arbeitendes Personal
- Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
- Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
- eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
- unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
- unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
- unsere umfassenden klinischen Aussagen
Testeinschränkungen
- Gene mit eingeschränkter Abdeckung werden gekennzeichnet
- Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
- es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
- die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
- Gen-Konversionen
- komplexe Inversionen
- Balancierte Translokationen
- Mitochondriale Varianten
- Repeat-Expansionen, sofern nicht anders dokumentiert
- nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
- niedriger Mosaik-Status
- Repeat-Blöcke von Mononukleotiden
- Indels >50bp (Insertionen-Deletionen)
- Deletionen oder Duplikationen einzelner Exons
- Varianten innerhalb von Pseudogenen
- die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde
Laboratory requirement
Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.
Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.
Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.
Die Untersuchung wird auch für Selbstzahler angeboten.